ALK Inhibitors for Non-small Cell Lung Cancer| A Pipeline Analysis Report 2018| Technavio

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180709005764/en/

Technavio has published a new report on the drug development pipeline for ALK inhibitors for NSCLC, including a detailed study of the pipeline molecules. (Photo: Business Wire)

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME ONLY: VIEW MARKET SNAPSHOT BEFORE PURCHASING

ALK inhibitors for non-small cell lung cancer: Market overview

Non-small cell lung cancer (NSCLC) is a major type of lung cancer. Lung cancer develops when lung cells start to grow uncontrollably. NSCLC can be further categorized into subtypes based on types of lung cells involved, i.e., squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, but they are clustered together as NSCLC due to similar treatment and prognosis approach.

According to a senior market research analyst at Technavio for research on oncology, “The ALK fusion gene, which is a component in the lung cells, gets abnormally activated in NSCLC. This can result in uncontrolled cell growth. The abnormal activation of the gene takes place due to alteration of ALK gene.”

ALK inhibitors for non-small cell lung cancer: Segmentation analysis

This pipeline analysis report segments the ALK inhibitors for non-small cell lung cancer market based on therapies employed (monotherapy and undisclosed), RoA (oral and undisclosed), therapeutic modalities (small molecules and disclosed), drugs under development (discovery, pre-clinical, phase I, phase I/II, phase II, and phase III), and recruitment status (recruiting, active not recruiting, enrolling by invitation, and undisclosed). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST A FREE SAMPLE REPORT

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

• Drugs under development
• Indications coverage

Drug Development Strategies

• Therapies employed
• RoA
• Therapeutic modality
• Geographical coverage

Recruitment Strategies

• Recruitment status
• Gender
• Age

Key Companies

• Type of players
• Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180709005764/en/